MEK inhibitors in oncology: a patent review (2015-Present)

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma

(2017) Jin Zhou et al.   Nature Communications

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

(2016) Vivek Asati et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

(2016) J. E. Grilley-Olson et al.   INVESTIGATIONAL NEW DRUGS

Combination therapy of melanoma using kinase inhibitors

(2015) Markus V. Heppt et al.   CURRENT OPINION IN ONCOLOGY

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity

(2015) K E Duncan et al.   EYE

Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

(2013) Asif Qazi et al.   Anti-Cancer Agents in Medicinal Chemistry

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

MEK inhibitors: a patent review 2008 – 2010

(2011) John I Trujillo   EXPERT OPINION ON THERAPEUTIC PATENTS

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Expression of TNF-superfamily members BAFF and APRIL in breast cancer: Immunohistochemical study in 52 invasive ductal breast carcinomas

(2008) Vassiliki Pelekanou et al.   BMC CANCER

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA